Company Overview
About Trace Neuroscience
Trace Neuroscience launched with $101 million in Series A financing from Third Rock Ventures, Atlas Venture, GV (Google Ventures), and RA Capital Management, developing TRCN-1023 — an antisense oligonucleotide (ASO) that corrects UNC13A mRNA splicing defects that have been genetically validated as a driver of ALS (amyotrophic lateral sclerosis). The company went directly to ALS patient enrollment in early 2026, bypassing the healthy volunteer phase typical of first-in-human trials, reflecting confidence in the mechanism's tolerability profile.
Business Model & Competitive Advantage
UNC13A is among the most genetically validated targets in ALS: genome-wide association studies across tens of thousands of patients have identified UNC13A variants as the primary genetic risk modifier determining ALS disease progression rate. The ASO's mechanism — correcting splicing of UNC13A mRNA to restore normal protein function — addresses a genetic pathway affecting approximately 97% of ALS patients, versus existing approved therapies that target only the ~5% of patients with specific familial mutations.
Competitive Landscape 2025–2026
The direct patient enrollment (skipping healthy volunteer phase) is clinically significant: ALS is a rapidly fatal disease where patients cannot afford the 6-12 month timeline that healthy volunteer trials add to clinical development. Regulators support accelerated timelines for unmet-need conditions, and Trace's direct enrollment signals both regulator concurrence and strong IND safety data.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
Trace Neuroscience is an emerging player bringing innovative solutions to the BioTech market.
Growth Stage
Trace Neuroscience has achieved $101M in revenue, demonstrating strong product-market fit.
Frequently Asked Questions
Not So Random Others
a2z Radiology AI
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disea
Adept AI
Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and exec
Duckie
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit
Plenty
Plenty is a San Francisco-based indoor vertical farming company that uses AI, machine learning, and robotics to grow leafy greens and other produce in controlled indoor environments. The company has r
Oura
Oura is the maker of the Oura Ring, a premium smart ring that tracks sleep, recovery, readiness, and health metrics through continuous biometric sensing. The company raised $900 million in Series E fi
Nira Energy
Nira Energy is a Denver-based renewable energy software company providing grid capacity mapping and interconnection analysis tools that help solar, battery storage, and data center developers identify
Compare Trace Neuroscience with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Trace Neuroscience? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Trace Neuroscience Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Trace Neuroscience vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →